Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-214 Monotherapy in Advanced Solid Tumors
NCT02869295Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of bempegaldesleukin in solid tumor, sponsored by Nektar Therapeutics. Started Dec 2015; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02869295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869295.